Drug Trial Radar · NCT07642505
L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
133
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Beni-Suef UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Erectile dysfunction is a common male sexual health problem that may affect quality of life and sexual relationships. Tadalafil 5 mg once daily is an established oral treatment for erectile dysfunction. L-citrulline is an oral nitric oxide pathway supplement that may improve erectile function by increasing L-arginine availability. This randomized trial will compare three oral treatment regimens in men with mild to moderate erectile dysfunction: L-citrulline 1500 mg/day, tadalafil 5 mg/day, and the combination of L-citrulline 1500 mg/day plus tadalafil 5 mg/day. Participants will receive treatment for 12 weeks and will be followed at baseline, week 4, week 8, and week 12. The primary outcome will be the change in the International Index of Erectile Function-Erectile Function domain score from baseline to 12 weeks. Secondary outcomes will include changes in IIEF-5/SHIM score, Erection Hardness Score, SEP diary outcomes, treatment adherence, adverse events, and treatment discontinuation.
Conditions
- Erectile Dysfunction
Interventions
L-CitrullineDrug
Oral L-citrulline 1500 mg/day administered for 12 weeks as an active oral nitric oxide pathway supplement for men with mild to moderate erectile dysfunction.
TadalafilDrug
Oral tadalafil 5 mg once daily administered for 12 weeks as active phosphodiesterase type 5 inhibitor therapy for men with mild to moderate erectile dysfunction.
L-Citrulline PlaceboDrug
Oral placebo preparation matching L-citrulline, administered for 12 weeks as part of the double-dummy design
Tadalafil PlaceboDrug
Oral placebo preparation matching tadalafil, administered for 12 weeks as part of the double-dummy study design.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in International Index of Erectile Function-Erectile Function Domain ScoreTime frame: Baseline to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Urology- Beni-Suef University Hospitals
Banī Suwayf, Beni Suweif Governorate, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.